State Street Corp lifted its position in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 20.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 629,903 shares of the company’s stock after buying an additional 106,321 shares during the quarter. State Street Corp owned about 0.38% of Dr. Reddy’s Laboratories worth $26,545,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of Dr. Reddy’s Laboratories by 34.8% in the second quarter. Royal Bank of Canada now owns 3,460,613 shares of the company’s stock worth $145,831,000 after buying an additional 893,138 shares during the last quarter. Commonwealth Bank of Australia lifted its stake in shares of Dr. Reddy’s Laboratories by 5.1% in the second quarter. Commonwealth Bank of Australia now owns 3,452,533 shares of the company’s stock worth $145,488,000 after buying an additional 168,818 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Dr. Reddy’s Laboratories by 5.4% in the first quarter. Vanguard Group Inc. now owns 1,549,609 shares of the company’s stock worth $62,217,000 after buying an additional 79,150 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Dr. Reddy’s Laboratories by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 573,738 shares of the company’s stock worth $24,155,000 after buying an additional 4,162 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Dr. Reddy’s Laboratories by 2.7% in the second quarter. Northern Trust Corp now owns 427,419 shares of the company’s stock worth $18,012,000 after buying an additional 11,378 shares during the last quarter. Institutional investors and hedge funds own 15.11% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “State Street Corp Has $26.55 Million Stake in Dr. Reddy’s Laboratories Ltd (RDY)” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/state-street-corp-has-26-55-million-stake-in-dr-reddys-laboratories-ltd-rdy/1701851.html.

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) opened at $35.51 on Tuesday. Dr. Reddy’s Laboratories Ltd has a 52-week low of $29.83 and a 52-week high of $49.41. The stock has a market cap of $5,904.93, a price-to-earnings ratio of 34.57, a P/E/G ratio of 10.41 and a beta of 0.40. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.08 and a current ratio of 1.46.

A number of equities analysts recently issued reports on RDY shares. CLSA lowered shares of Dr. Reddy’s Laboratories from an “underperform” rating to a “sell” rating in a research report on Friday, July 28th. BidaskClub lowered shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Jefferies Group LLC reaffirmed a “sell” rating and set a $31.62 target price on shares of Dr. Reddy’s Laboratories in a research report on Sunday, September 3rd. Morgan Stanley raised shares of Dr. Reddy’s Laboratories from an “equal weight” rating to an “overweight” rating in a research report on Thursday, September 21st. Finally, Zacks Investment Research raised shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Dr. Reddy’s Laboratories currently has a consensus rating of “Hold” and a consensus price target of $30.51.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Institutional Ownership by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.